GlassScriptPhysician profile
Preston Wilson
NPI 1952538605
$12,665.01
in general payments reported to CMS, 2019-2025
69 companies · $1,787 in 2025
The $1,787 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,646 · 2020: $1,091 · 2021: $2,027 · 2022: $1,882 · 2023: $2,026 · 2024: $2,207 · 2025: $1,787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,019.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,539.67 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $1,158.92 | 2019-2025 | Repatha, Evenity, Otezla |
| Astrazeneca Pharmaceuticals LP | $987.69 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $783.29 | 2019-2025 | |
| Astellas Pharma US INC | $714.13 | 2019-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $699.26 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $683.34 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $615.06 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Merck Sharp & Dohme LLC | $454.03 | 2019-2024 | M-M-R II, Gardasil 9, Vaxelis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $440.83 | 2019-2024 | Jardiance |
| Gilead Sciences, INC. | $335.04 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $308.78 | 2019-2025 | Spravato, Xarelto |
| Axsome Therapeutics, INC. | $225.00 | 2022-2025 | Sunosi, Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $201.50 | 2022-2025 | |
| Viiv Healthcare Company | $201.26 | 2023-2024 | Apretude |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Preston Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.